Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2013

View Archived Issues

A modified antibody treatment to prevent fetal death via alloimmunization in the mother

Preclinical evaluation of cell therapy to improve cognitive function after brain irradiation

Uncovering the role of epigenetic readers on gene transcription during heart failure pathogenesis

Patrys advances phase I/IIa trial of PAT-SM6 in MM to final patient group

Sucampo reports topline results from phase Ia trials of cobiprostone and SPI-3608

A.P. Pharma plans to change name and list common stock on NASDAQ

New protein Wnt inhibitors disclosed by Merck KGaA and Cancer Research UK

Onyx and Idis partner to launch carfilzomib managed access program in Europe

Bayer Intellectual Property discloses novel GnRH receptor antagonists

Synergy Pharmaceuticals to spin-off FV-100 assets

Intratumoral CVA21 shows safety and efficacy in phase II melanoma trial

FDA approves Alere Determine HIV-1/2 Ag/Ab Combo test

Epistem receives grant for point-of-care hepatitis C assays

Scripps receives National Institute on Aging grant to study human aging process

Suven Life Sciences characterizes agents acting on serotonin receptors for Alzheimer's disease

Quest Diagnostics launches opioid therapy genetic test

Rosetta Genomics and Tel Aviv University's Ramot receive cancer grant

Japanese authorities classify Evolva's resveratrol as non-drug food supplement

Aradigm receives NIH grant for gastroesophageal reflux aspirations

Prostate cancer research collaboration unites Berg with the U.S. Department of Defense

Stem Cell Therapeutics enters option agreement to license prostate cancer stem cell assets

NWBio receives clearance in Germany to proceed with phase III DCVax-L trial

Bio-Path's lead antisense therapeutic effective in blood cancers

Nuevolution, Howard Hughes Medical Institute, Lexicon and Duke University form collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...